The role of mast cell and airway smooth muscle interactions in the pathophysiology of asthma. (360G-Wellcome-082265_Z_07_Z)

£1,212,043

We hypothesise that airway hyperresponsiveness and persistent airflow obstruction in asthma result from a) intrinsic abnormalities in airway smooth muscle (ASM) from asthmatics and b) interactions between ASM-mast cells. We aim i) to examine the differences between ASM from asthmatics and non-asthmatics and to determine the mechanisms underlying these differences in terms of calcium homeostasis using single cell and FLIPR analysis; contractility using collagen gel contraction assays and single c ell measurements of maximal contraction and velocity; synthetic capacity using a variety of approaches including ELISA, immunoblotting, proteomics, qPCR and gene array; migration using 2D assays; proliferation by MTS assay and thymidine incorporation; and survival by Annexin V and PI staining, ii) to investigate in vitro the effect of ASM-mast cell interactions on ASM and mast cell function respectively and to confirm effects, as appropriate, in tissue and iii) to confirm that localisation of ac tivated mast cells in the ASM-bundle is a feature of asthma across severity of disease and to determine whether this is affected by corticosteroids or experimental viral infection. For the in vitro experiments we shall use freshly isolated and primary ASM cultures from bronchial biopsies from asthmatics and controls and primary mast cells from lung resection material.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 1212043
Applicant Surname Brightling
Approval Committee Clinical Interview Committee
Award Date 2007-06-07T00:00:00+00:00
Financial Year 2006/07
Grant Programme: Title Senior Research Fellowship Clinical
Internal ID 082265/Z/07/Z
Lead Applicant Prof Chris Brightling
Partnership Value 1212043
Planned Dates: End Date 2013-10-31T00:00:00+00:00
Planned Dates: Start Date 2007-11-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region East Midlands
Sponsor(s) Prof Peter Andrew